At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,797 enrolled
Drug / intervention
aCRT ON +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AdaptResponse Clinical Trial
In Brief
A clinical study evaluating aCRT ON and aCRT OFF for Heart Failure With Left Bundle Branch Block. Completed, enrolled 3,797 participants across 220 sites in 28 countries.
Detailed Summary
The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Russia, Saudi Arabia, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartAug 2014
Primary CompletionNov 2022
TodayJul 2026
First PostedJul 31, 2014
Enrollment StartAug 1, 2014
Primary CompletionNov 2, 2022
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 11.9 years ago
Interventions
aCRT ONdevice
CRT device with AdaptivCRT enabled (AdaptivBiV and LV)
aCRT OFFdevice
CRT device with AdaptivCRT disabled